Ultragenyx Pharmaceutical Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ultragenyx Pharmaceutical Inc. on August 17, 2014. The report discloses the execution of a material definitive agreement regarding the company's operational facilities.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figures disclosed relate to the amended facility agreement:
- Annual Rent: $305,000.00
- Monthly Rent: $25,416.67
- Right of First Refusal Fee: $73,872 per year for additional space
Material Changes
On August 17, 2014, the Company executed Amendment No. 2 to its License and Services Agreement with The Buck Institute for Research on Aging. Key changes include:
- Effective Date: September 15, 2014
- Term Extension: The agreement term is extended through September 15, 2019, with an option to extend for up to three additional consecutive twelve-month periods.
- Space and Equipment: The amendment provides additional laboratory and office space and grants an exclusive license to use certain equipment.
- Cost Increase: Rent has been increased to the amounts listed above.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of general business risks. The primary contingency noted is the option to extend the agreement term for up to three additional years.
Investor Verification Checklist
- Verify the impact of the increased annual rent ($305,000) on the company's operating expenses.
- Confirm the strategic necessity of the additional laboratory and office space at The Buck Institute.
- Review the terms of the exclusive equipment license to understand potential operational dependencies.
- Monitor future filings for the exercise of the option to extend the agreement term beyond 2019.